VITAMIN B₁₂ DEFICIENCY



For the Primer, visit doi:10.1038/nrdp.2017.40


Vitamin B₁₂ (B12) — also known as cobalamin — has an important role as a cofactor in many cellular processes, including DNA synthesis and methylation, and mitochondrial metabolism. Deficiency is associated with various symptoms, of which the haematological (mainly anaemia) and neurological (such as sensory and motor disturbances, ataxia and psychiatric disorders) manifestations are the most characteristic.

EPIDEMIOLOGY

Clinical B12 deficiency associated with either severe anaemia or neurological manifestations or both is uncommon (1–2% of individuals >60 years of age), but subclinical deficiency affects 3-26% of the general population in the United States, depending on the biomarker cut-off levels used. Prevalence is much higher in South America, Asia and Africa. Demand and availability of B12 varies throughout life, making specific subpopulations vulnerable to deficiency, especially infants, children, women who are pregnant or breastfeeding and elderly individuals.




Risk factors for developing B12 deficiency are failure of the intrinsic intake of B12-containing foods (mainly meat), genetic factors, gastrointestinal infection or surgery, long-term use of drugs (such as gastric H⁺/K⁺ inhibitors or histamine H2 receptor antagonists) and concomitant illnesses such as HIV infection and tuberculosis.



DIAGNOSIS

As the clinical presentation of B12 is so varied, a combination of blood biomarkers is often used for diagnosis, despite limitations. These markers include low total B12 levels and transcobalaminbound B12 levels (that is, the active form of B12), and increased homocysteine and methylmalonic acid levels. However, the exact cut-off levels to classify normal, subclinical or clinical B12



MANAGEMENT

Depending on the underlying cause, B12 repletion

generally involves oral (if the cause is inadequate intake) or parenteral (if the cause involves malabsorption) B12 administration. After a high initial load, the dose is usually reduced.

increased homocysteine

levels in populations receiving

folic-acid-fortified products or

in individuals using folic acid

and increased homocysteine

levels have been associated

with cognitive impairment in

elderly individuals.

public health concern, especially

in developing countries and in

populations at risk. In addition,

correction of B12 levels